Novel urinary biomarkers in pre-diabetic nephropathy

Clinical and Experimental Nephrology

Volumn 19, Issue 5, 2015, Pages 895-900

  Garg, Vikas ^a   Kumar, Manish ^a   Mahapatra, Himansu Sekhar ^a   Chitkara, Anubhuti ^a   Gadpayle, Adesh Kumar ^a   Sekhar, Venketansan ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

Cystatin C; Diabetic nephropathy; NGAL; Pre diabetes

Indexed keywords

CYSTATIN C; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CREATININE; CST3 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPID; LIPOCALIN; ONCOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSOCIATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; URINE ALBUMIN CREATININE RATIO; ALBUMINURIA; BLOOD; KIDNEY FUNCTION TEST; MIDDLE AGED; URINE;

ACUTE-PHASE PROTEINS; ADULT; ALBUMINURIA; BIOMARKERS; CREATININE; CYSTATIN C; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; LIPIDS; LIPOCALINS; MALE; MIDDLE AGED; PREDIABETIC STATE; PROTO-ONCOGENE PROTEINS;

EID: 84944162078     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1085-3     Document Type: Article

References (38)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37:s81–90.
2. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177–86.
3. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease dependent mechanism of albuminuria. Am J Physiol Renal Physiol. 2008;295:F1589–600.
4. Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34.
5. Molitch ME, Steffes M, Sun W, Epidemiology of Diabetes Interventions and Complications Study Group, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536–43.
6. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.
7. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.
8. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361–8.
9. Jeon YK, Kim MR, Huh JE, Mok JY, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.
10. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1144–50.
11. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.
12. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, et al. Cystatin C as a marker of GFR -history, indications, and future research. Clin Biochem. 2005;38:1–8.
13. Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol. 2003;285:F9–18.
14. Mishra J, Ma Q, Prada A, Mitsnefes M, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–43.
15. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–15.
16. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–8.
17. Kim SS, Song SH, Kim IJ, Jeon YK, et al. Urinary Cystatin C and Tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care. 2013;36:656–61.
18. Nauta FL, Boertien WE, Bakker SJL, Goor HV, et al. Glomerular markers are elevated in patients with diabetes. Diabetes Care. 2011;34:975–81.
19. Wu J, Ding Y, Zhu C, Shao X, et al. Urinary TNF-α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp Ther Med. 2013;6:1482–8.
20. Fu WJ, Li BL, Wang SB, Chen ML, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract. 2012;95(1):105–9.
21. Holman RR, Paul SK, Bethel MA, Matthews DR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
22. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol. 2006;17(S2):S90–7.
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.
24. Borgman JM, Skorecki K. Chronic kidney disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL,editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2308–2321.
25. Levey AS, Bosch JP, Lewis JB, Green T, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.
26. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis. 2004;44(5):792–8.
27. Tarsio JF, Reger LA, Furcht LT. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association. Diabetes. 1988;37(5):532–9.
28. Duncan ER, Walker SJ, Ezzat VA, Wheatcroft SB, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab. 2007;293:E1311–9.
29. Makris K, Nikolaki E, Nanopoulos K, Pirqakis KM, et al. Measurement of Cystatin C in human urine by particle enhanced turbidimetric immunoassay on automated biochemistry analyzer. Clin Biochem. 2013;46(12):1128–30.
30. Conti M, Moutereau S, Zater M, Lallali K, et al. Urinary Cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med. 2006;44(3):288–91.
31. Woo KS, Choi JL, Kim BR, Kim JE, et al. Urinary neutrophil gelatinase-associated lipocalin levels in comparison with glomerular filtration rate for evaluation of renal function in patients with diabetic chronic kidney disease. Diabetes Metab J. 2012;36:307–13.
32. Lacquaniti A, Donato V, Pintaudi B, Vieste GD, et al. ‘‘Normoalbuminuric’’ diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50:935–42.
33. Assal HS, Tawfeek S, Rasheed EA, Lebedy DE, et al. Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus. Clin Med Insights Endocrinol Diab. 2013;6:7–13.
34. Fu WJ, Xiong SL, Fang YG, Wen S, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012;41(1):82–8.
35. Mori K, Lee HT, Rapoport D, Drexler IR, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–21.
36. Kaseda R, Iino N, Hosojima M, Takeda T, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007;357(4):1130–4.
37. Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200–8.
38. Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol. 2006;17:2937–44.